Literature DB >> 27200801

Work Productivity Improvement Associated With Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis Results Of A Phase 3, Randomized, Controlled Trial.

F Zhang1, T Tencer1, S Li1, V Strand2.   

Abstract

Entities:  

Year:  2014        PMID： 27200801     DOI： 10.1016/j.jval.2014.08.2572

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  2 in total

Review 1.  Apremilast: A Review in Psoriasis and Psoriatic Arthritis.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2015-08       Impact factor: 9.546

2.  What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials.

Authors:  Sibel Bakirci Ureyen; Catherine Ivory; Umut Kalyoncu; Jacob Karsh; Sibel Zehra Aydin
Journal:  Rheumatol Adv Pract       Date:  2018-01-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.